Using a clonogenic survival assay, they showed that treating U251 and LN229 (p53 mutant, PTEN wild type) glioma cell lines with a combination of TMZ and CQ resulted in a more pronounced reduction in colony formation than each drug alone. Here, TP53 is linked to central nervous system cancer.